Suggested remit: To appraise the clinical and cost effectiveness of mezigdomide with dexamethasone and carfilzomib within its marketing authorisation for treating relapsed or refractory multiple myeloma after at least 1 line of treatment.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6513
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 July 2026 | Awaiting development. The National Institute for Health and Care Excellence (NICE) has been asked to conduct an evaluation of Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment. We have recently invited stakeholders to respond to a written consultation on the draft scope. Following an update from the company responsible for Mezigdomide, NICE will not be progressing with this scoping exercise at this time and the timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. Please accept our apologies for any inconvenience at this late stage. |
| 01 June 2026 - 29 June 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6513 |
| 01 June 2026 | In progress. Scoping commencing |
| 06 January 2026 | Note - Note added to the project documents |
| 30 September 2025 | Awaiting development. Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late June 2026 when we will write to you about how you can get involved. |
| 16 April 2025 | Referral |
| 14 November 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual